Challenging Alzheimer's: Korean Firms Forge Ahead In Multiple Modalities
Hopes RIse As Diverse Contenders Enter Late-Stage Trials
Scrip takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.
You may also be interested in...
Korea's AriBio is poised to file for US Phase III trial approval this year for its novel Alzheimer's candidate and lead asset AR1001, which showed an improvement in cognitive function from baseline at Phase II. But will the benefits over existing therapies be enough to carve a position in the challenging field?
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.